Skip to main content Back to Top
Advertisement

3/20/2020

Etomidate Injection

Products Affected - Description

    • Amidate injection, Pfizer, 2 mg/mL, 20 mL LifeShield syringe, 10 count, NDC 00409-8060-29
    • Etomidate injection, Athenex, 2 mg/mL, 10 mL vial, 10 count, NDC 70860-0652-10
    • Etomidate injection, AuroMedics, 2 mg/mL, 10 mL vial, 10 count, NDC 55150-0221-10
    • Etomidate injection, Zydus, 2 mg/mL, 10 mL vial, 10 count, NDC 68382-0545-07 - discontinued
    • Etomidate injection, Zydus, 2 mg/mL, 20 mL vial, 10 count, NDC 68382-0545-08 - discontinued

Reason for the Shortage

    • American Regent is not currently marketing etomidate.
    • Athenex did not provide a reason for the current shortage.
    • AuroMedics did not provide a reason for the current shortage.
    • Hikma has etomidate available.
    • Mylan Institutional has etomidate available.
    • Par Sterile Products discontinued etomidate in early 2015.
    • Pfizer has Amidate on shortage due to manufacturing delays. Pfizer discontinued etomidate ampules in October 2016.
    • Sagent is no longer marketing etomidate.
    • Zydus did not provide a reason for the shortage.

Available Products

    • Amidate injection, Pfizer, 2 mg/mL, 10 mL vial, 10 count, NDC 00409-6695-01
    • Amidate injection, Pfizer, 2 mg/mL, 20 mL vial, 10 count, NDC 00409-6695-02
    • Etomidate injection, Athenex, 2 mg/mL, 20 mL vial, 10 count, NDC 70860-0652-20
    • Etomidate injection, AuroMedics, 2 mg/mL, 20 mL vial, 10 count, NDC 55150-0222-20
    • Etomidate solution for injection, Fosun Pharma, 2 mg/mL, 10 mL vial, 10 count, NDC 72266-0146-10
    • Etomidate solution for injection, Fosun Pharma, 2 mg/mL, 20 mL vial, 10 count, NDC 72266-0147-10
    • Etomidate injection, Hikma, 2 mg/mL, 10 mL vial, 10 count, NDC 00143-9506-10
    • Etomidate injection, Hikma, 2 mg/mL, 20 mL vial, 10 count, NDC 00143-9507-10
    • Etomidate injection, Mylan Institutional, 2 mg/mL, 10 mL vial, 10 count, NDC 67457-0902-10
    • Etomidate injection, Mylan Institutional, 2 mg/mL, 20 mL vial, 10 count, NDC 67457-0903-20

Estimated Resupply Dates

    • Athenex has etomidate 2 mg/mL 10 mL and 20 mL vials on back order and the company cannot estimate a release date.
    • AuroMedics has etomidate 2 mg/mL 10 mL vials on intermittent back order and the company is releasing product as it becomes available.
    • Pfizer has Amidate 2 mg/mL 20 mL LifeShield syringes on back order and the company estimates a release date of March 2020.

Safety

    • Clinicians must take extra care to ensure safe use of etomidate when using different presentations than those normally stocked.

Updated

Updated March 20, 2020 by Michelle Wheeler, PharmD, Drug Information Specialist. Created July 6, 2011 by Jane Chandramouli, PharmD, Drug Information Specialist. © 2020, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins


ahfs logo

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.